CD20

[Haematologica] Tafasitamab combined with the immunomodulatory drug lenalidomide was clinically active with a good tolerability profile in the open-label, single-arm, phase II L-MIND study of autologous stem-cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.

[Digestive and Liver Disease] Autoimmune hepatitis is a chronic inflammatory liver disease affecting all ages, characterized by elevated transaminase and immunoglobulin G levels, positive autoantibodies, interface hepatitis on histology and good response to immunosuppressive treatment.

[Bristol Myers Squibb] Bristol Myers Squibb announced positive results from TRANSFORM, a Phase III study evaluating Breyanzi as a second-line treatment in adults with relapsed or refractory large B-cell lymphoma compared to salvage therapy followed by high-dose chemotherapy and hematopoietic stem cell transplant.

[TG Therapeutics, Inc. (Globe Newswire, Inc.)] TG Therapeutics, Inc. announced that the FDA has accepted the Biologics License Application for Ublituximab, the company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQ®, their inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

[Nature Biomedical Engineering] Researchers reported the generation of hypoimmunogenic cancer-antigen-specific T cells derived from induced pluripotent stem cells lacking β2-microglobulin, the class-II major histocompatibility complex transactivator and the natural killer cell-ligand poliovirus receptor CD155, and expressing single-chain MHC class-I antigen E.

[Angiogenesis] The authors highlight the phenotype and function of high endothelial venules (HEVs) in homeostatic, inflamed and tumor-draining lymph nodes, and those of HEV-like blood vessels in chronic inflammatory diseases.